Professional Documents
Culture Documents
500WestMainStreet
P.O.Box1438
Louisville,KY402011438
http://www.humana.com
FORMOREINFORMATIONCONTACT:
AmySmith
HumanaInvestorRelations
(502)5802811
email:Asmith3@humana.com
TomNoland
HumanaCorporateCommunications
(502)5803674
email:Tnoland@humana.com
HumanaReportsSecondQuarter2017FinancialResults;
RaisesFullYear2017Guidance;
ProvidesUpdateonBonusYear2018StarRatings
2Q17earningsperdilutedcommonshare(EPS)of$4.46onaGAAPbasis,$3.49AdjustedEPS
Fullyear2017guidanceraisedtoapproximately$17.83EPSonaGAAPbasis,approximately$11.50AdjustedEPS
IndividualMedicareAdvantageresultssignificantlyoutperformingmanagementsoriginalexpectations
Approximately74percentofthecompanysMedicareAdvantagemembersarenowexpectedtobein4Starplansor
higherforbonusyear2018
LOUISVILLE,KY(August2,2017)HumanaInc.(NYSE:HUM)todayreporteddilutedearningspercommonshare(EPS)
forthequarterendedJune30,2017(2Q17)versusthequarterendedJune30,2016(2Q16)andforthesixmonths
endedJune30,2017(1H2017)versusforthesixmonthsendedJune30,2016(1H2016)asfollows:
Consolidatedpretaxincome
2Q17(a) 2Q16(b) 1H2017(c) 1H2016(d)
Inmillions
GenerallyAcceptedAccountingPrinciples(GAAP) $1,042 $636 $2,731 $1,136
Net(gain)expensesassociatedwiththeterminatedmergeragreement(for1H2017,
primarilythebreakupfee) 27 (947) 61
Amortizationassociatedwithidentifiableintangibles 18 20 36 41
GuarantyfundassessmentexpensetosupportthepolicyholderobligationsofPenn
Treaty(anunaffiliatedlongtermcareinsurancecompany) 54
Operating(income)lossesassociatedwiththeIndividualCommercialbusiness (118) 225 (181) 237
Adjusted(nonGAAP)2Q16and1H2016asrecast $942 $908 $1,693 $1,475
Dilutedearningspercommonshare(EPS) 2Q17(a) 2Q16(b) 1H2017(c) 1H2016(d)
ThecompanyhasincludedfinancialmeasuresthroughoutthisearningsreleasethatarenotinaccordancewithGAAP.Managementbelievesthatthesemeasures,whenpresentedin
conjunctionwiththecomparableGAAPmeasures,areusefultobothmanagementanditsinvestorsinanalyzingthecompanysongoingbusinessandoperatingperformance.Consequently,
managementusesthesenonGAAPfinancialmeasuresasindicatorsofthecompanysbusinessperformance,aswellasforoperationalplanninganddecisionmakingpurposes.NonGAAP
financialmeasuresshouldbeconsideredinadditionto,butnotasasubstitutefor,orsuperiorto,financialmeasurespreparedinaccordancewithGAAP.Allfinancialmeasuresinthispress
releaseareinaccordancewithGAAPunlessotherwiseindicated.
Withthecompletionofourfirstfullquartersincethedealbreak,Humanasstrong2Q17resultsandincreaseinfull
yearguidancedemonstratethestrengthofourintegratedcaredeliverystrategy,saidBruceD.Broussard,Humanas
PresidentandChiefExecutiveOfficer.Itsourtalentedteamthatsmadethispossible.Throughoutthelengthydeal
period,ourassociatesneverwaveredintheirfocusandcommitmenttoourmembers,providerpartnersand
shareholders.Itsbecauseofthisthatwecontinuetomakestridesinadvancingourstrategywhiledeliveringstrong
operatingperformance.
TheGAAPconsolidatedpretaxincomefor2Q17of$1.04billionrose$406million,or64percent,comparedtoGAAP
consolidatedpretaxincomeof$636millionin2Q16primarilyduetoyearoveryearimprovementinearningsforthe
companysindividualMedicareAdvantageandIndividualCommercialbusinesses,partiallyoffsetbylowerpretax
earningsintheGroupandSpecialtyandHealthcareServicessegments.
TheAdjustedconsolidatedpretaxincomefor2Q17of$942millionrose$34million,or4percent,versus$908millionin
2Q16primarilyreflectingthesamefactorsimpactingtheGAAPcomparison,whileexcludingtheimpactoftheitems
detailedintheconsolidatedpretaxincometableabove.
GAAPconsolidatedpretaxincomefor1H2017of$2.73billionincreased$1.60billion,or140percent,from$1.14billion
in1H2016.Theincreaseprimarilyreflectsthenetgainassociatedwiththeterminatedmergeragreement,mainlythe
breakupfeerecognizedinthefirstquarterof2017,alongwiththefactorsimpactingthesecondquartercomparison.
TheAdjustedconsolidatedpretaxincomefor1H2017of$1.69billionincreased$218million,or15percent,versus
$1.48billionin1H2016primarilyreflectingthesamefactorsimpactingtheGAAPcomparison,whileexcludingthe
impactofitemsnotedinthetableabove.
Furtherdiscussionsofeachsegmentsfinancialresultsareincludedinthesegmenthighlightsbelow.
TheyearoveryearchangesinGAAPEPSfor2Q17and1H2017reflectedthesamefactorsimpactingtheGAAP
consolidatedpretaxincomecomparisonsyearoveryearaswellasthebeneficialeffectofthelowereffectivetaxratein
lightofpricingandbenefitdesignassumptionsassociatedwiththetemporarysuspensionofthehealthinsurance
industryfeein2017.TheyearoveryearincreasesinAdjustedEPSfor2Q17and1H2017reflectedthesamefactors
impactingtheAdjustedconsolidatedpretaxincomecomparisonsyearoveryear.Inaddition,thesecondquarterand
yeartodatecomparisonsofbothGAAPandAdjustedEPSarefavorablyimpactedbyalowernumberofsharesusedto
computeEPS,primarilyreflectingsharerepurchasesinthefirstquarterof2017,includingthepreviouslydisclosed
acceleratedstockrepurchase(ASR)program.
WearepleasedthatourindividualMedicareAdvantagebusinessissignificantlyoutperformingourprevious
expectations,reflectingourfocusonoperationalexcellenceandthesolidexecutionofourstrategy,saidBrianA.Kane,
SeniorVicePresidentandChiefFinancialOfficer.Wewerethereforeabletoinvestthisoutperformancein2018benefit
designs,resultinginstableandcompetitivebenefitsfor2018despitecertainheadwinds,inparticularthereturnofthe
healthinsuranceindustryfee.
2017EarningsGuidance
HumanatodayraiseditsGAAPandAdjustedEPSguidancefortheyearendingDecember31,2017(FY17).FY17GAAP
EPSwasincreasedtoapproximately$17.83fromthepreviousguidanceofatleast$16.91,whileAdjustedEPSwas
increasedtoapproximately$11.50fromthepreviousguidanceofatleast$11.10.TheincreasesinFY17guidancefor
bothGAAPandAdjustedEPSwereprimarilydrivenbythestrongresultsintheRetailsegment,largelyattributabletothe
companysindividualMedicareAdvantagebusiness,partiallyoffsetbylowerthanexpectedHealthcareServicessegment
pretaxincomeduetolowerthananticipatedpharmacyutilizationandthecontinuedoptimizationofourchroniccare
managementprograms.TheindividualMedicareAdvantagebusinessisexceedingitsoperationaltargets,experiencing
lowerthananticipatedutilization,higherthanexpectedrevenueonapermemberbasisandfavorablemedicalfeefor
serviceclaimsreservedevelopment(PriorPeriodDevelopment).AdditionalFY17guidancepointsandarollforwardfrom
previousguidanceareincludedinthetablesbeginningonpage24ofthisearningspressrelease.
AreconciliationofGAAPtoAdjustedEPSforthecompanysFY17projectionsaswellascomparablenumbersforthe
yearendedDecember31,2016(FY16)isshownbelow:
FY17
Dilutedearningspercommonshare Guidance(e) FY16(f)
GAAP ~$17.83 $4.07
Net(gain)expensesassociatedwiththeterminatedmergeragreement(forFY17,primarilythebreak
upfee) (4.36) 0.64
Amortizationofidentifiableintangibles 0.31 0.32
Beneficialeffectoflowereffectivetaxrateinlightofpricingandbenefitdesignassumptionsassociated
withthe2017temporarysuspensionofthenondeductiblehealthinsuranceindustryfee;
excludesIndividualCommercialbusinessimpact (2.15)
Reservestrengtheningforthecompanysnonstrategicclosedblockoflongtermcareinsurance
business(g) 2.11
GuarantyfundassessmentexpensetosupportthepolicyholderobligationsofPennTreaty(an
unaffiliatedlongtermcareinsurancecompany) 0.24
OperatingresultsassociatedwiththeIndividualCommercialbusinessgiventhecompanysexiton
January1,2018aspreviouslydisclosed (0.37) 3.78
Adjusted(nonGAAP)FY17projected;FY16asrecast ~$11.50 $10.92
StarQualityRatings
Thecompanynowexpects74percentofitsJune30,2017MedicareAdvantagemembershiptobein4Starplansor
higherforbonusyear2018.Aspreviouslydisclosed,inOctober2016,theCentersforMedicareandMedicaidServices
(CMS)publisheditsStarqualityratings(Starratings)showingthatthepercentageofthecompanysJuly31,2016
MedicareAdvantagemembershipin4Starplansorhigherdeclinedtoapproximately37percentforbonusyear2018
comparedtoapproximately78percentofthecompanysJuly31,2015membershipforbonusyear2017.WhileStar
ratingsarebasedonanumberofplanperformancemeasuresthatareevaluatedeachyear,theprojectedStarratings
forthecompanysplansforthe2018bonusyearincludedcertainreductionsthatwereprimarilyattributabletothe2015
comprehensiveprogramauditbyCMS.ThecompanyfiledareconsiderationrequestwithCMS,whichwasdenied.The
companysubsequentlydecidednottoappealthatdenialfurther,andworkedthroughexistingCMSprocessesto
rationalizecontractstructures,resultinginfinalStarratingsforbonusyear2018thatreflectitscommitmenttoquality
productsandservicesforitsmembers.ThecompanyremainscommittedtoitspartnershipwithCMSandtodelivering
qualityproductsandservicestoitsmembers.
HumanaConsolidatedHighlights
Consolidatedrevenues
Consolidatedrevenues 2Q17(a) 2Q16(b) 1H2017(c) 1H2016(d)
(inmillions)
GAAP $13,534 $14,007 $27,296 $27,807
RevenuesassociatedwithIndividualCommercialbusiness (248) (1,025) (532) (1,920)
Adjusted(nonGAAP)2Q16and1H2016asrecast $13,286 $12,982 $26,764 $25,887
GAAPconsolidatedrevenuesfor2Q17were$13.53billion,adecreaseof$473million,or3percent,from$14.01billion
in2Q16.Totalpremiumsandservicesrevenuesof$13.43billionin2Q17decreased$479million,or3percentfrom
$13.91billionin2Q16.TheyearoveryeardecreasesprimarilyreflectlowerIndividualCommercialsegmentrevenues,
partiallyoffsetbyhigherRetailsegmentrevenuesprimarilyresultingfromthecompanysMedicarebusiness.
Adjustedconsolidatedrevenuesfor2Q17of$13.29billioncomparedtoAdjustedconsolidatedrevenuesfor2Q16of
$12.98billion,anincreaseof$304million,or2percent,reflectinghigherRetailsegmentrevenuesprimarilyassociated
withthecompanysMedicarebusiness,whileexcludingtheimpactofrevenuesassociatedwiththecompanysIndividual
Commercialbusiness.
Consolidatedrevenuesfor1H2017decreased$511million,or2percent,to$27.30billionfrom$27.81billionin1H
2016.Totalpremiumsandservicesrevenuesalsodeclinedto$27.08billionin1H2017,decreasing$528million,or2
percent,from$27.61billionintheprioryearperiod.The1H2017decreaseswereprimarilydrivenbythesamefactors
impactingthesecondquartercomparison.
Adjustedconsolidatedrevenuesfor1H2017of$26.76billioncomparedtoAdjustedconsolidatedrevenuesfor1H2016
of$25.89billion,anincreaseof$877million,or3percent,reflectinghigherRetailsegmentrevenuesprimarily
4
associatedwiththecompanysMedicarebusiness,whileexcludingtheimpactofrevenuesassociatedwiththe
companysIndividualCommercialbusiness.
Consolidatedbenefitsexpense
The2Q17GAAPconsolidatedbenefitratioof82.5percentdecreased180basispointsfrom84.3percentfor2Q16
primarilyreflectingtheimpactoftheIndividualCommercialbusiness,plannedexitsfromcertainMedicareAdvantage
marketsthatcarriedahigherbenefitratio,andhigherfavorablePriorPeriodDevelopment.Theyearoveryear
comparisonwasfavorablyimpactedbythe$208millionincreaseinthepremiumdeficiencyreserve(PDR)recordedin
2Q16relatedtocertainofthecompanys2016IndividualCommercialpoliciesaswellasexitsin2017fromcertain
marketsthatcarriedahigherbenefitratioandpermemberpremiumincreaseyearoveryear.Theseimprovements
werepartiallyoffsetbytheimpactofthetemporarysuspensionofthehealthinsuranceindustryfeein2017whichwas
contemplatedinthepricingandbenefitdesignofthecompanysproductsandmargincompressionassociatedwiththe
competitiveenvironmentinthegroupMedicareAdvantagebusiness.
The2Q17Adjustedconsolidatedbenefitratioof83.4percentincreased90basispointsfromthe2Q16Adjusted
consolidatedbenefitratioof82.5percent.Theyearoveryearincreaseprimarilyreflectstheimpactofthetemporary
suspensionofthehealthinsuranceindustryfeein2017whichwascontemplatedinthepricingandbenefitdesignofthe
companysproductsandmargincompressionassociatedwiththecompetitiveenvironmentinthegroupMedicare
Advantagebusiness,partiallyoffsetbyplannedexitsfromcertainMedicareAdvantagemarketsthatcarriedahigher
benefitratio,andhigherfavorablePriorPeriodDevelopment,whileexcludingtheimpactofthecompanysIndividual
Commercialbusiness.
TheGAAPconsolidatedbenefitratiofor1H2017of83.5percentdecreased110basispointsfromthe1H2016GAAP
consolidatedbenefitratioof84.6percent.Theyearoveryeardecreaseprimarilyreflectsthesamefactorsimpacting
thesecondquarterGAAPconsolidatedbenefitratiocomparisonaswellastheseasonalimpactofaleapdayin1H2016,
partiallyoffsetbylowerfavorablePriorPeriodDevelopment.
The1H2017Adjustedconsolidatedbenefitratioof84.3percentincreased50basispointsfromthe1H2016Adjusted
consolidatedbenefitratioof83.8percent.Theyearoveryearincreaseprimarilyreflectsthesamefactorsimpactingthe
secondquarterAdjustedconsolidatedbenefitratiocomparisonandlowerfavorablePriorPeriodDevelopment,while
excludingtheimpactofthecompanysIndividualCommercialbusiness.
ConsolidatedPriorPeriodDevelopment(inmillions) FirstQuarter
Favorable(unfavorable) Individual
Commercial AllOther Total
PriorPeriodDevelopmentfromprioryearsrecognizedinfirstquarterof2017 $6 $225 $231
PriorPeriodDevelopmentfromprioryearsrecognizedinfirstquarterof2016 $80 $260 $340
SecondQuarter
PriorPeriodDevelopmentfromprioryearsrecognizedinsecondquarterof2017 $20 $94 $114
PriorPeriodDevelopmentfromprioryearsrecognizedinsecondquarterof2016 $17 $78 $95
YeartoDate
PriorPeriodDevelopmentfromprioryearsrecognizedin1H2017 $26 $319 $345
PriorPeriodDevelopmentfromprioryearsrecognizedin1H2016 $97 $338 $435
PriorPeriodDevelopmentfor2Q17and2Q16isshownaboveanddecreasedtheGAAPconsolidatedbenefitratioby90
basispointsin2Q17andby70basispointsin2Q16,reflectingaslightlyhigherleveloffavorabledevelopmentinthe
RetailandGroupandSpecialtysegments.PriorPeriodDevelopmentloweredthe1H2017consolidatedbenefitratioby
130basispointsversusby160basispointsin1H2016.
Consolidatedoperatingexpenses
The2Q17GAAPconsolidatedoperatingcostratio(operatingcostsasapercentoftotalrevenueslessinvestment
income)of10.8percentdecreased140basispointsfrom12.2percentin2Q16primarilyreflectingthetemporary
suspensionofthehealthinsuranceindustryfeein2017,partiallyoffsetbythelossofscaleefficiencyfrommarketexits
in2017associatedwiththecompanysIndividualCommercialproduct.Thenondeductiblehealthinsuranceindustryfee
increasedtheconsolidatedGAAPoperatingcostratiobyapproximately160basispointsin2Q16.
The2Q17Adjustedconsolidatedoperatingcostratioof10.7percentdecreased130basispointsfromthe2Q16Adjusted
consolidatedoperatingcostratioof12.0percentprimarilydrivenbythesamefactorsimpactingthechangeintheGAAP
consolidatedoperatingcostratio,whileexcludingtheimpactoftheitemsdetailedintheconsolidatedoperatingcost
ratiotableabove.
The1H2017GAAPconsolidatedoperatingcostratioof11.1percentdecreased130basispointsfrom12.4percentin1H
2016primarilyreflectingthetemporarysuspensionofthehealthinsuranceindustryfeein2017,partiallyoffsetbythe
lossofscaleefficiencyfrommarketexitsin2017associatedwiththecompanysIndividualCommercialproductandthe
guarantyfundassessmentexpenserecognizedinthefirstquarterof2017tosupportthepolicyholderobligationsofan
unaffiliatedlongtermcareinsurancecompany.Thenondeductiblehealthinsuranceindustryfeeincreasedthe
consolidatedGAAPoperatingcostratiobyapproximately170basispointsin1H2016.
The1H2017Adjustedconsolidatedoperatingcostratioof10.7percentdeclined140basispointsfrom12.1percentin
1H2016primarilyreflectingthesamefactorsimpactingtheGAAPcomparison,whileexcludingtheimpactoftheitems
notedintheconsolidatedoperatingcostratiotableabove.
Balancesheet
Cash,cashequivalentsandinvestmentsecurities
AtJune30,2017,thecompanyhadcash,cashequivalents,andinvestmentsecuritiesof$18.92billion,down
$130million,or1percent,from$19.05billionatMarch31,2017,primarilyreflectingthenetrepaymentof$270
millionassociatedwiththecompanyscommercialpaperprogramandcapitalexpenditures,partiallyoffsetby
netreceiptsfromCMSassociatedwithMedicarePartDclaimsubsidiesforwhichthecompanydoesnotassume
risk.
AtJune30,2017,cashandshortterminvestmentsheldattheparentcompanyof$2.82billionincreased$1.11
billion,or65percent,from$1.71billionatMarch31,2017,primarilyreflectingdividendsreceivedfrom
subsidiariesduring2Q17,partiallyoffsetbythenetrepaymentof$270millionassociatedwiththecompanys
commercialpaperprogram,capitalexpenditures,capitalcontributionsintocertainsubsidiaries,andcash
dividendspaidtostockholders.Subsidiarydividendstotheparentcompanyof$1.35billionin2Q17compared
to$663millionin2Q16.Parentcompanycashandshortterminvestmentsincluded$200millionassociated
withoutstandingcommercialpaperatJune30,2017and$470millionatMarch31,2017.
Premiumstabilizationprograms(3Rs)receivables
AtJune30,2017,netreceivablesof$411millionwereassociatedwiththe3Rswithdetailofthenetreceivables
(payables)forthe3Rsasfollows.Aspreviouslyannounced,thecompanyisexitingthisbusinessonJanuary1,
2018.
Asdisclosedpreviously,inthefourthquarterof2016thecompanywroteoffallreceivablesassociatedwiththe
commercialriskcorridorprogram.AtJune30,2017,thecompanyestimatesthatitisentitledtocollectatotalof
7
$611millionfromtheDepartmentofHealthandHumanaServices(HHS)underthecommercialriskcorridor
programforthe2014through2016programyears.
Benefitspayable
Thecompanycalculatesdaysinclaimspayable(DCP)usingthequarterlyreportedbenefitsexpenseandbenefits
payablebalancesaspresentedwithinthecompanysconsolidatedfinancialstatements,adjustingsolelyfor
reservestrengthening,ifany,forthecompanysnonstrategicclosedblockoflongtermcareinsurancebusiness
anditsimpactonfuturepolicybenefitsexpense,suchasthatfromthefourthquarterof2016.
ThecompanysmethodologyresultsinalowerlevelofDCPversusthesectoratlargeandislikelyduetothe
companysconcentrationofbusinessinMedicareAdvantageandstandalonePDPofferings,includingutilization
patternsofprescriptionsamongtheseniorpopulation,andthespeedofprocessingassociatedwithHumana
Medicaremedicalandpharmacyclaims.
DCPof40.4atJune30,2017,increased2.6daysfrom37.8atMarch31,2017butdeclined1.2daysfrom41.6at
June30,2016.Thesequentialincreaseprimarilyresultedfromtheseasonalimpactofprovideraccrualsfor
capitationpaymentsandmedicalfeeforserviceclaims,excludingtheIndividualCommercialbusiness.Theyear
overyeardeclineprimarilyresultedfromthelossofmembersinthecompanysIndividualCommercialbusiness.
Debttototalcapitalization
DebttototalcapitalizationatJune30,2017was31.3percent,down260basispointsfrom33.9percentat
March31,2017,primarilyresultingfromhighercapitalfromthenetimpactof2Q17earningsandthenet
repaymentof$270millionassociatedwiththecompanyscommercialpaperprogram.Thecompanyslong
termtargetdebttototalcapitalizationrangeof30to35percentisexpectedtoallowthecompanytomaintain
itsinvestmentgradecreditratingwhileprovidingsignificantfinancialflexibility.
Operatingcashflows
Netcashfromoperatingactivities
(inmillions) 2Q17 2Q16 1H2017 1H2016
Providedby(usedin)
GAAP ($106) ($296) $4,099 $206
TimingofpremiumpaymentfromCMS(i) 23 (3,050)
Adjusted(nonGAAP) ($83) ($296) $1,049 $206
GAAPcashflowsusedinoperationsof$106millionin2Q17favorablycomparedtocashflowsusedin
operationsof$296millionin2Q16primarilyduetohigherearningsyearoveryearandthetimingofworking
capitalchanges,partiallyoffsetbytheportionoftaxespaidin2Q17relatedtothemergerterminationfee.
GAAPcashflowsusedinoperationsin2Q17werenotsignificantlyimpactedbythetimingofthepremium
paymentfromCMS,astheearlyreceiptoftheAprilMedicarepremiumpaymentfromCMSof$3.07billionin
thefirstquarterof2017wassubstantiallyoffsetbytheearlyreceiptoftheJulyMedicarepremiumpayment
fromCMSof$3.05billionin2Q17.Adjustedcashflowsusedinoperationsfor2Q17of$83millioncompared
8
favorablytocashflowsusedinoperationsof$296millionin2Q16duetothesameitemsdrivingtheGAAP
increase,excludingtheimpactofthetimingofthepremiumpaymentfromCMS.
For1H2017,cashflowsprovidedbyoperationstotaled$4.10billionversus$206millionofcashflowsprovided
byoperationsduring1H2016,apositivechangeof$3.89billionyearoveryear,primarilyreflectingtheearly
receiptoftheJulyMedicarepremiumpaymentfromCMSof$3.05billionin2Q17,thereceiptofthemerger
terminationfee,netofrelatedexpensesandtheportionoftaxespaidtodate,andhigherearnings,partially
offsetbyworkingcapitalchanges.1H2017operatingcashflowsincludedsevenmonthlyMedicarepremium
paymentsfromCMScomparedtosixmonthlypaymentsin1H2016.
Sharerepurchases
InFebruary2017,HumanasBoardofDirectorsapproveda$2.25billionsharerepurchaseauthorizationwithan
expirationdateofDecember31,2017andthecompanysubsequentlyenteredintoanagreementwithathird
partyfinancialinstitutiontoeffecta$1.50billionASRprogramundertheauthorization.Theactualnumberof
sharesrepurchasedundertheagreementwillbedeterminedbasedonavolumeweightedaveragepriceofthe
companyscommonstockduringthepurchaseperiod.Settlementofapproximately$300millionofrepurchases
undertheASRprogramremainspending,andthecompanyexpectsfinalsettlementbytheendofthethird
quarterof2017.
GiventheoutstandingASR,thecompanydidnotexecuteanysharerepurchasesin2Q17.Through1H2017,the
companyexecutedsharerepurchasesofapproximately5,833,700shares,atanaveragepriceof$205.70per
shareundertheASRprogram.Duetothethenpendingmergeragreement,thecompanydidnotrepurchase
anysharesin2Q16or1H2016.AsofAugust1,2017,approximately$1.05billionofthecurrentrepurchase
authorizationwasremaining,includingthe$300millionheldbackaspartoftheASRprogramdescribedabove.
Cashdividends
Thecompanypaidcashdividendstoitsstockholdersof$57millionin2Q17and$43millionin2Q16.Cash
dividendsof$104millionwerepaidtothecompanysstockholdersduring1H2017and$90millionin1H2016.
HumanasRetailSegment
ThissegmentconsistsofthecompanysMedicarebenefits,marketedtoindividualsdirectlyorviagroupMedicare
accounts,aswellasitsMedicareSupplementandstatebasedcontractsbusinesses.Statebasedcontractsincludethose
withvariousstatestoprovideMedicaid,dualeligible,andLongTermSupportServicesbenefits.Inaddition,this
segmentalsoincludesthecompanyscontractwiththeCentersforMedicareandMedicaidServicestoadministerthe
LimitedIncomeNewlyEligibleTransitionprescriptiondrugplanprogram.
Retailsegmentrevenues:
The2Q17revenuesfortheRetailsegmentwere$11.30billion,anincreaseof$341million,or3percent,from
$10.96billionin2Q16primarilyreflectinghigherrevenuesassociatedwiththecompanysMedicareAdvantage
businessresultingfromincreasedmembership,aswellasincreasedpermemberpremiumsforcertain
businesseswithinthesegment.
The1H2017revenuesfortheRetailsegmentwere$22.73billion,anincreaseof$872million,or4percent,from
$21.86billionin1H2016primarilyreflectingthesamefactorsimpactingthesecondquartercomparison.
Retailsegmentenrollment:
IndividualMedicareAdvantagemembershipwas2,840,100asofJune30,2017,anetincreaseof23,600,or1
percent,from2,816,500atJune30,2016,anduplessthan1percentfrom2,837,600asofDecember31,2016.
Currentmembershiplevelsprimarilyreflecttheeffectofmarketandproductexits.Thecompanydecided
certainmarketsand/orproductswerenotmeetinglongtermstrategicandfinancialobjectives.Additionally,
membershipgrowthwasmutedduetocompetitiveactionsincludingtheuncertaintyassociatedwiththethen
pendingtransaction.
GroupMedicareAdvantagemembershipwas433,400asofJune30,2017,anetincreaseof81,700,or23
percent,from351,700atJune30,2016,andup78,000,or22percent,from355,400atDecember31,2016,
primarilyduetotheadditionofalargeaccountinJanuary2017.
MembershipinthecompanysstandalonePDPofferingswas5,236,400asofJune30,2017,anetincreaseof
380,100,or8percent,from4,856,300atJune30,2016,andup285,000,or6percent,from4,951,400asof
December31,2016.TheseincreasesprimarilyresultedfromgrowthinthecompanyslowpriceHumana
Walmartplanoffering.
Statebasedcontractsmembership(includingdualeligibledemonstrationmembers)was374,900asofJune30,
2017,anetdecreaseof16,700,or4percent,from391,600atJune30,2016,anddown13,200,or3percent,
from388,100atDecember31,2016.Thedecreaseswereprimarilydrivenbylowermembershipassociatedwith
thecompanysFloridacontractsresultingfromnetworkrealignments.
10
Retailsegmentbenefitsexpense:
The2Q17benefitratiofortheRetailsegmentof85.8percentincreased50basispointsfrom85.3percentin
2Q16primarilyduetotheimpactofthetemporarysuspensionofthehealthinsuranceindustryfeein2017
whichwascontemplatedinthepricingandbenefitdesignofthecompanysproductsandmargincompression
associatedwiththecompetitiveenvironmentinthegroupMedicareAdvantagebusiness.Thisincreasewas
partiallyoffsetbytheimpactofplannedexitsfromcertainMedicareAdvantagemarketsthatcarriedahigher
benefitratiothanothermarkets.
The1H2017benefitratiofortheRetailsegmentof87.0percentwas10basispointshigherthanthe1H2016
ratioof86.9percentprimarilyreflectingthesamefactorsimpactingtheyearoveryearcomparisonsforthe
secondquarter,aswellastheseasonalimpactofaleapdayin1H2016.
Retail segment Prior Period Development (in millions) First Second First
Favorable (unfavorable) quarter quarter Half
Prior Period Development from prior years recognized in 1H 2017 $204 $83 $287
Prior Period Development from prior years recognized in 1H 2016 $218 $81 $299
TheRetailsegmentPriorPeriodDevelopmentof$83millionin2Q17comparedtofavorabledevelopmentof$81
millionin2Q16.PriorPeriodDevelopmentfortheRetailsegmentfor1H2017decreasedto$287million
comparedto$299millionin1H2016reflectingslightlyunfavorableyearoveryearcomparisonsrelatingtothe
companysMedicarebusiness.
PriorPeriodDevelopmentdecreasedtheRetailsegmentbenefitratioby70basispointsin2Q17andin2Q16.
PriorPeriodDevelopmentloweredthe1H2017segmentbenefitratioby130basispointsandby140basis
pointsin1H2016.
Retailsegmentoperatingcosts:
TheRetailsegmentsoperatingcostratioof8.5percentin2Q17decreased130basispointsfrom9.8percentin
2Q16primarilyduetothetemporarysuspensionofthehealthinsuranceindustryfeein2017.
TheRetailsegments1H2017operatingcostratioof8.5percentdecreased140basispointsfrom9.9percent
in1H2016reflectingthesamefactorimpactingtheyearoveryearcomparisonsforthesecondquarter.
ThenondeductiblehealthinsuranceindustryfeeincreasedtheRetailsegmentsGAAPoperatingcostratioby
approximately170basispointsin2Q16andin1H2016.
11
Retailsegmentpretaxresults:
Retailsegmentpretaxincome
2Q17(a) 2Q16(b) 1H2017(c) 1H2016(d)
inmillions
GAAP $607 $514 $977 $655
Amortizationassociatedwithidentifiableintangibles 6 6 12 12
Adjusted(nonGAAP)2Q16and1H2016asrecast $613 $520 $989 $667
TheRetailsegmentsGAAPpretaxincomeof$607millionin2Q17increased$93million,or18percent,froma
GAAPpretaxincomeforthesegmentof$514millionin2Q16,primarilyduetotheyearoveryearimprovement
inearningsforthecompanysindividualMedicareAdvantagebusiness.
AdjustedpretaxincomefortheRetailsegmentof$613millionin2Q17increased$93million,or18percent,
from$520millionin2Q16reflectingthesamefactorsimpactingtheGAAPcomparison,whileexcludingthe
impactoftheamortizationassociatedwithidentifiableintangiblesdetailedintheRetailsegmentpretaxincome
tableabove.
For1H2017,GAAPpretaxincomefortheRetailSegmentof$977millionincreasedby$322million,or49
percent,whileAdjustedpretaxincomefortheRetailsegmentof$989billionin1H2017increased$322million,
or48percent,from$667millionofAdjustedpretaxincomefortheRetailsegmentin1H2016.BoththeGAAP
andAdjustedyearoveryearincreasesresultedfromthesamefactorimpactingthesecondquarter
comparisons.
12
HumanasGroupandSpecialtySegment
Thissegmentconsistsofthecompanysemployergroupfullyinsuredcommercialmedicalproductsandspecialtyhealth
insurancebenefitsmarketedtoindividualsandgroups,includingdental,vision,andothersupplementalhealthand
voluntaryinsurancebenefits.Inaddition,thesegmentalsoincludesthecompanysadministrativeservicesonly(ASO)
productsanditsmilitaryservicesbusinesses,primarilytheTRICARESouthRegioncontract.
GroupandSpecialtysegmentrevenues:
The2Q17revenuesfortheGroupandSpecialtysegmentwere$1.83billion,down$43million,or2percent,
from$1.87billionin2Q16,primarilyreflectingdeclinesinaveragegroupfullyinsuredandASOcommercial
medicalmembership,partiallyoffsetbyanincreaseingroupfullyinsuredcommercialmedicalpermember
premiums.
The1H2017revenuesfortheGroupandSpecialtysegmentwere$3.71billion,down$15million,orlessthan1
percent,from$3.72billionin1H2016,primarilyreflectingthesamefactorsimpactingthesecondquarter
comparison.
GroupandSpecialtysegmentenrollment:
Groupfullyinsuredcommercialmedicalmembershipwas1,107,500atJune30,2017,adecreaseof32,600,or3
percent,from1,140,100atJune30,2016,anddown28,500,or3percent,from1,136,000atDecember31,
2016.Thechangesarereflectiveoflowermembershipinsmallgroupaccountsdueinparttomoresmallgroup
accountsselectingASOproductsin2017.Theportionofgroupfullyinsuredcommercialmedicalmembership
insmallgroupaccounts(299sizedemployergroups)wasapproximately65percentatJune30,2017andat
December31,2016versus66percentatJune30,2016.
GroupASOcommercialmedicalmembershipwas446,800atJune30,2017,adecreaseof131,600,or23
percent,from578,400atJune30,2016,anddown126,400,or22percent,from573,200atDecember31,2016.
Thedeclinesprimarilyreflectthelossofcertainlargegroupaccountsduetocontinueddisciplineinpricingof
servicesforselffundedaccountsamidahighlycompetitiveenvironment,partiallyoffsetbymoresmallgroup
accountsselectingASOproductsin2017.Smallgroupmembershipcomprised7percentofgroupASOmedical
membershipatJune30,2017versus2percentatJune30,2016and4percentatDecember31,2016.
Militaryservicesmembershipwas3,088,600atJune30,2017,anincreaseof13,800,orlessthan1percent,
from3,074,800atJune30,2016,andup4,500,orlessthan1percentversus3,084,100atDecember31,2016.
Membershipinspecialtyproducts(j)was6,917,800atJune30,2017,adecreaseof84,500,or1percent,from
7,002,300atJune30,2016,anddown43,400,or1percent,from6,961,200atDecember31,2016.The
decreasesprimarilyareattributabletodeclinesinothersupplementalbenefitsmembership,aswellasdeclines
inindividualdentalmembershipfollowingHumanasexitfromcertainindividualcommercialmedicalmarketsin
2017.Othersupplementalbenefitsincludelife,disability,andfixedbenefitproductsincludingcancerandcritical
illnesspolicies.
13
GroupandSpecialtysegmentbenefitsexpense:
The2Q17benefitratiofortheGroupandSpecialtysegmentwas78.4percent,anincreaseof100basispoints
from77.4percentfor2Q16.Theyearoveryearincreaseinthebenefitratioprimarilyreflectstheimpactofthe
temporarysuspensionofthehealthinsuranceindustryfeein2017whichwascontemplatedinthepricingofthe
companysproductsandanincreasedproportionofsmallgroupmembersincommunityratedplansthatcarrya
higherbenefitratio.TheseincreaseswerepartiallyoffsetbyhigherfavorablePriorPeriodDevelopmentin2Q17.
The1H2017benefitratiofortheGroupandSpecialtysegmentof77.0percentwas150basispointshigherthan
the1H2016ratioof75.5percentprimarilyduetothesamefactorsimpactingtheyearoveryearcomparisons
forthesecondquarter,aswellastheimpactoflowerfavorablePriorPeriodDevelopmentyearoveryearfor1H
2017.
Group and Specialty segment Prior Period Development (in First quarter Second First Half
millions) quarter
Favorable (unfavorable)
Prior Period Development from prior years recognized in 1H 2017 $20 $11 $31
Prior Period Development from prior years recognized in 1H 2016 $41 ($3) $38
TheGroupandSpecialtysegmentPriorPeriodDevelopmentof$11millionin2Q17comparedtounfavorable
developmentof$3millionin2Q16.ThisincreaseprimarilyrelatedtothefavorablePriorPeriodDevelopment
associatedwiththecompanyssmallgroupproducts.PriorPeriodDevelopmentfortheGroupandSpecialty
segmentfor1H2017decreasedto$31millioncomparedto$38millionin1H2016reflectingthelessfavorable
PriorPeriodDevelopmentassociatedwiththecompanysfullyinsuredcommercialmedicalproducts.
PriorPeriodDevelopmentdecreasedthe2Q17GroupandSpecialtysegmentbenefitratioby70basispointsbut
increasedtheratioby20basispointsin2Q16.PriorPeriodDevelopmentloweredthe1H2017segmentbenefit
ratioby90basispointsandby110basispointsin1H2016.
GroupandSpecialtysegmentoperatingcosts:
TheGroupandSpecialtysegmentsoperatingcostratiowas21.6percentin2Q17,adecreaseof110basis
pointsfrom22.7percentin2Q16,primarilyduetothetemporarysuspensionofthehealthinsuranceindustry
feein2017partiallyoffsetbytheimpactofthetimingofrevenuesunderthecompanysTRICAREcontract
primarilyrelatingtomedicalcosttrendincentivesandamountsforadditionalservicesrequestedunderthe
contract.
TheGroupandSpecialtysegmentsoperatingcostratioof21.5percentfor1H2017wasdown160basispoints
comparedto23.1percentfor1H2016primarilyreflectingthesamefactorsimpactingtheyearoveryear
comparisonforthesecondquarter.
ThenondeductiblehealthinsuranceindustryfeenegativelyimpactedtheGroupandSpecialtysegments
operatingcostratiobyapproximately140basispointsin2Q16andby150basispointsin1H2016.
14
GroupandSpecialtysegmentpretaxresults:
GroupandSpecialtysegmentpretaxincome
2Q17(a) 2Q16(b) 1H2017(c) 1H2016(d)
Inmillions
GAAP $101 $124 $272 $296
Amortizationassociatedwithidentifiableintangibles 1 2 2 4
Adjusted(nonGAAP)2Q16and1H2016asrecast $102 $126 $274 $300
TheGroupandSpecialtysegmentsGAAPpretaxincomeof$101millionin2Q17comparedtoGAAPpretax
incomeof$124millionin2Q16,adecreaseof$23million,or19percent.Thedeclineprimarilyreflectsthe
timingofrevenuesunderthecompanysTRICAREcontractprimarilyrelatingtomedicalcosttrendincentives
andamountsforadditionalservicesrequestedunderthecontract.
TheAdjustedpretaxincomefortheGroupandSpecialtysegmentof$102millionin2Q17decreased$24million,
or19percent,from$126millionofAdjustedpretaxincomein2Q16reflectingthesamefactorsimpactingthe
quarterlyGAAPcomparison,whileexcludingtheimpactofamortizationassociatedwithidentifiableintangibles.
TheGroupandSpecialtysegmentsGAAPpretaxincomeof$272millionin1H2017comparedtoGAAPpretax
incomeof$296millionin1H2016,adecreaseof$24million,or8percent.Adjustedpretaxincomeforthe
GroupandSpecialtysegmentof$274millionin1H2017decreased$26million,or9percent,from$300million
inAdjustedpretaxincomein1H2016.ThefirsthalfyearoveryearchangesforbothGAAPandAdjustedpretax
incomefortheGroupandSpecialtysegmentprimarilyreflectedthesamefactorsimpactingthequarterly
comparisons.
15
HumanasHealthcareServicesSegment
Thissegmentincludesservicesofferedtothecompanyshealthplanmembersaswellastothirdparties,including
pharmacysolutions,providerservices,andclinicalprograms,suchashomehealthandotherservicesandcapabilitiesto
promotewellnessandadvancepopulationhealth.
ServicesofferedbythissegmentaredesignedtoenhancemembershealthcareexperiencewithHumanaoverall.These
servicesmayleadtolowerutilizationassociatedwithimprovedmemberhealthand/orlowerdrugcosts.
HealthcareServicessegmentrevenues:
Revenueof$5.98billionin2Q17fortheHealthcareServicessegmentdecreased$306million,or5percent,from
$6.29billionin2Q16.Thedeclineprimarilywasduetothecompanyspharmacysolutionsbusinessandthe
resultoftheoptimizationprocessassociatedwiththecompanyschroniccaremanagementprogramsdiscussed
below,aswellasongoingpressuresinthecompanysproviderservicesbusinessreflectinglowerMedicarerates
yearoveryearingeographieswherethecompanysproviderassetsareprimarilylocated.Thecompanys
pharmacysolutionsbusinessrevenueswereimpactedbyimprovementsinnetpharmacycostsdrivenbythe
companyspharmacybenefitmanagerandanincreaseinthegenericdispensingrate.Theseitemswerepartially
offsetbyhigheryearoveryearscriptvolumefromgrowthinthecompanysMedicareAdvantageandstand
alonePDPmembershipandtheimpactoflowerIndividualCommercialmembership.Thecompanysgeneric
dispensingrateimprovedto91.1%during2Q17comparedto90.2%during2Q16.Thehighergenericdispensing
ratereducedrevenues(andoperatingcosts)forthecompanyspharmacysolutionsbusinessasgenericdrugs
aregenerallypricedlowerthanbrandeddrugs.
1H2017revenuefortheHealthcareServicessegmentwas$11.94billion,adecreaseof$578million,or5
percent,from$12.52billionin1H2016primarilyreflectingthesamefactorsimpactingtheyearoveryear
comparisonforthesecondquarter.Thecompanysgenericdispensingrateimprovedto91.2%during1H2017
comparedto90.2%during1H2016.
HealthcareServicessegmentoperatingcosts:
TheHealthcareServicessegmentsoperatingcostratioof95.0percentin2Q17wasrelativelyunchanged
comparedtothe2Q16ratioof95.1percent.
TheHealthcareServicessegmentsoperatingcostratioof95.2percentfor1H2017wasalsorelatively
unchangedcomparedto95.3percentfor1H2016.
HealthcareServicessegmentoperatingstatistics:
Primarycareprovidersinvaluebased(sharedriskandpathtorisk)relationshipsof50,700atJune30,2017
increased5percentfrom48,200atJune30,2016andincreased1percentfrom50,400atDecember31,2016.
AtJune30,2017,65percentofthecompanysindividualMedicareAdvantagememberswereinvaluebased
relationshipscomparedto61percentatJune30,2016and64percentatDecember31,2016.
16
MedicareAdvantageanddualdemonstrationprogrammembershipenrolledinaHumanachroniccare
managementprogramwas981,600atJune30,2017,down3percentfrom1,008,100atJune30,2016and
down11percentfrom1,099,200atDecember31,2016.Thecompanyhasundergoneanoptimizationprocess
thatensurestheappropriatelevelofmemberinteractionwithclinicianstodrivequalityoutcomesleadingto
reducedsegmentearningsbuthigherreturnsoninvestment.
Pharmacyscriptvolumeonanadjusted30dayequivalentbasisof108millionfor2Q17increased3percent
comparedto105millionfor2Q16.Pharmacyscriptvolumeof215millionfor1H2017increased3percent
comparedto209millionfor1H2016.TheseincreasesprimarilyweredrivenbyhigherMedicaremembership,
partiallyoffsetbythedeclineinIndividualCommercialmembership.
HealthcareServicessegmentpretaxresults:
HealthcareServicessegmentpretaxincome
2Q17(a) 2Q16(b) 1H2017(c) 1H2016(d)
(inmillions)
GAAP $270 $279 $514 $531
Amortizationassociatedwithidentifiableintangibles 11 12 22 24
Adjusted(nonGAAP)2Q16and1H2016asrecast $281 $291 $536 $555
HealthcareServicessegmentGAAPpretaxincomeof$270millionin2Q17decreasedby$9million,or3percent,
fromGAAPpretaxincomeof$279millionin2Q16primarilyduetotheongoingpressuresinthecompanys
providerservicesbusinessreflectinglowerMedicareratesyearoveryearingeographieswherethecompanys
providerassetsareprimarilylocated,aswellastheimpactoftheoptimizationprocessassociatedwiththe
companyschroniccaremanagementprogramsdiscussedabove.Thereductioninpharmacyrevenues,also
discussedabove,wasoffsetbyasimilarreductioninoperatingcostsassociatedwiththepharmacysolutions
business.
Adjustedpretaxincomein2Q17fortheHealthcareServicessegmentof$281millionwasdown$10million,or3
percent,comparedto$291millionin2Q16reflectingthesamefactorsimpactingthequarterlyGAAP
comparison,whileexcludingtheimpactofamortizationassociatedwithidentifiableintangibles.
1H2017GAAPpretaxincomefortheHealthcareServicessegmentof$514milliondecreasedby$17million,or3
percent,from1H2016GAAPpretaxearningsof$531million.ThesegmentsAdjustedpretaxincomefor1H
2017of$536milliondecreased$19million,or3percent,versusthe1H2016Adjustedpretaxincomeforthe
HealthcareServicessegmentof$555million.ThefirsthalfyearoveryearchangesforbothGAAPandAdjusted
pretaxincomefortheHealthcareServicessegmentprimarilyreflectedthesamefactorsimpactingthequarterly
comparisons.
17
HumanasIndividualCommercialSegment
ThissegmentconsistsofthecompanysIndividualCommercialproductsmarketedundertheHumanaOnebrand.For
2017,thecompanyoffersonexchangeproductsaswellascertaingrandfatheredpoliciesissuedpriortotheenactment
oftheHealthCareReformLaw.Offexchangeproductswerealsoofferedin2016.Asannouncedin2017,thecompany
planstoexitthisbusinessin2018.ResultsofthissegmenthavebeenexcludedfromconsolidatedAdjustedresults,with
priorperiodsbeingrecast.
IndividualCommercialsegmentenrollment:
IndividualCommercialmembershipof181,100asofJune30,2017,wasdown610,900,or77percent,from
792,000atJune30,2016,anddown473,700,or72percent,from654,800atDecember31,2016.Thedecreases
primarilyreflectedthedeclineinnumberofcountieswherethecompanyoffersonexchangecoverage,aswell
asthediscontinuanceofofferingoffexchangeproducts.
IndividualCommercialsegmentbenefitsexpense:
The2Q17benefitratiofortheIndividualCommercialsegmentwas34.8percent,adecreasefrom106.3percent
for2Q16.Theyearoveryeardecreaseprimarilyresultedfromtheeffectofthe$208millionincreaseinthePDR
recordedin2Q16relatedtocertainofthecompanys2016policies,plannedexitsin2017incertainmarketsthat
carriedahigherbenefitratio,andpermemberpremiumincreases.
The1H2017benefitratiofortheIndividualCommercialsegmentwas45.7percent,adecreasefrom94.8
percentfor1H2016primarilyreflectingthesamefactorsimpactingthesecondquartercomparisons.
IndividualCommercialsegmentoperatingcosts:
TheIndividualCommercialsegmentsoperatingcostratiowas16.2percentin2Q17,anincreaseof140basis
pointsfrom14.8percentin2Q16,primarilyduetothelossofscaleefficiencyfrommarketexitsin2017partially
offsetbythetemporarysuspensionofthehealthinsuranceindustryfeein2017.
The1H2017operatingcostratiofortheIndividualCommercialsegmentwas19.2percent,anincreaseof250
basispointsfrom16.7percentin1H2016primarilyreflectingthesamefactorsimpactingthesecondquarter
comparisons.
IndividualCommercialsegmentpretaxresults:
TheIndividualCommercialsegmentspretaxincomeof$118millionin2Q17comparedtoapretaxlossof$225
millionin2Q16,anincreaseof$343million,primarilyreflectingtheimpactofthe$208millionincreaseinthe
PDRrecordedin2Q16relatedtocertainofthecompanys2016policiesaswellastheexitofcertainmarketsin
2017andpermemberpremiumincreases.
18
The Individual Commercial segments pretax income of $181 million in 1H 2017 compared to a pretax loss of
$237millionin1H2016,anincreaseof$418million,reflectingthesamefactorsimpactingthesecondquarter
comparisons.
ConferenceCall
Humanawillhostaconferencecallat9:00a.m.easterntimetodaytodiscussitsfinancialresultsforthequarterandthe
companysexpectationsforfutureearnings.
Allpartiesinterestedintheaudioonlyportionofthecompanys2Q17earningsconferencecallareinvitedtodial888
6257430.Nopasswordisrequired.Awebcastofthe2Q17earningscallmayalsobeaccessedviaHumanasInvestor
Relationspageathumana.com.Thecompanysuggestsparticipantsforboththeconferencecallandthoselisteningvia
thewebdialinorsignonatleast15minutesinadvanceofthecall.
Forthoseunabletoparticipateintheliveevent,thearchivewillbeavailableintheHistoricalWebcastsand
PresentationssectionoftheInvestorRelationspageathumana.com,approximatelytwohoursfollowingthelive
webcast.Telephonereplayswillalsobeavailableapproximatelytwohoursfollowingtheliveeventuntilmidnight
easterntimeonOctober2,2017andcanbeaccessedbydialing8558592056andprovidingtheconferenceID
#89803304.
19
Footnotes
(a) 2Q17Adjustedresultsexcludethefollowing:
Amortizationexpenseforidentifiableintangiblesofapproximately$18millionpretax,or$0.08perdilutedcommonshare;GAAP
measuresaffectedinthisreleaseincludeconsolidatedpretax,EPS,andsegmentpretaxresults(foreachsegmentsamountofsuch
amortization).
Theoneyearbeneficialeffectofalowereffectivetaxrateofapproximately$0.54perdilutedcommonshareinlightofpricingand
benefitdesignassumptionsassociatedwiththe2017temporarysuspensionofthenondeductiblehealthinsuranceindustryfee;
excludesIndividualCommercialbusinessimpact.GAAPmeasuresaffectedinthisreleaseincludeconsolidatedEPS.
Operatingearningsofapproximately$118millionpretax,or$0.51perdilutedcommonshare,forthecompanysIndividual
CommercialbusinessgiventhecompanysplannedexitonJanuary1,2018,aspreviouslydisclosed.GAAPmeasuresaffectedinthis
releaseincludeconsolidatedpretaxincome,EPS,consolidatedrevenues,consolidatedbenefitratioandconsolidatedoperatingcost
ratio.
(b) 2Q16Adjustedresults(recast)excludethefollowing:
Transactionandintegrationcostsof$27millionpretax,or$0.16perdilutedcommonshare,associatedwiththethenpending
mergeragreement;GAAPmeasuresaffectedinthisreleaseincludeconsolidatedpretaxincomeandEPS.
Amortizationexpenseforidentifiableintangiblesofapproximately$20million,or$0.08perdilutedcommonshare;GAAPmeasures
affectedinthisreleaseincludeconsolidatedpretax,EPS,andsegmentpretaxresults(foreachsegmentsamountofsuch
amortization).
Operatinglossesof$225millionpretax,or$0.99perdilutedcommonshare,forthecompanysIndividualCommercialbusiness
giventhecompanysplannedexitonJanuary1,2018,aspreviouslydisclosed.GAAPmeasuresaffectedinthisreleaseinclude
consolidatedpretaxincome,EPS,consolidatedrevenues,consolidatedbenefitratioandconsolidatedoperatingcostratio.
(c) 1H2017Adjustedresultsexcludethefollowing:
Netgainfromtheterminationofthemergeragreementofapproximately$947millionpretax,or$4.31perdilutedcommonshare;
includesthenetbreakupfeeandtransactioncostsnetofthetaxbenefitassociatedwithcertainexpenseswhichwerepreviously
nondeductible;GAAPmeasuresaffectedinthisreleaseincludeconsolidatedpretaxincomeandEPS.
Amortizationexpenseforidentifiableintangiblesofapproximately$36millionpretax,or$0.16perdilutedcommonshare;GAAP
measuresaffectedinthisreleaseincludeconsolidatedpretax,EPS,andsegmentpretaxresults(foreachsegmentsamountofsuch
amortization).
Theoneyearbeneficialeffectofalowereffectivetaxrateofapproximately$1.06perdilutedcommonshareinlightofpricingand
benefitdesignassumptionsassociatedwiththe2017temporarysuspensionofthenondeductiblehealthinsuranceindustryfee;
excludesIndividualCommercialbusinessimpact.GAAPmeasuresaffectedinthisreleaseincludeconsolidatedEPS.
Guarantyfundassessmentexpenseofapproximately$54millionpretax,or$0.23perdilutedcommonshare,tosupportthe
policyholderobligationsofPennTreaty(anunaffiliatedlongtermcareinsurancecompany);GAAPmeasuresaffectedinthisrelease
includeconsolidatedpretaxincome,EPS,andconsolidatedoperatingcostsratio. Understateguarantyassessmentlaws,the
companymaybeassessed(uptoprescribedlimits)forcertainobligationstothepolicyholdersandclaimantsofinsolventinsurance
companiesthatwritethesamelineorlinesofbusinessasthecompany.OnMarch1,2017,acourtorderedtheliquidationofPenn
Treatywhichtriggeredassessmentsfromthestateguarantyassociations.
Operatingearningsofapproximately$181millionpretax,or$0.77perdilutedcommonshare,forthecompanysIndividual
CommercialbusinessgiventhecompanysplannedexitonJanuary1,2018,aspreviouslydisclosed.GAAPmeasuresaffectedinthis
releaseincludeconsolidatedpretaxincome,EPS,consolidatedrevenues,consolidatedbenefitratioandconsolidatedoperatingcost
ratio.
(d) 1H2016Adjustedresults(recast)excludethefollowing:
Transactionandintegrationcostsof$61millionpretax,or$0.37perdilutedcommonshare,associatedwiththethenpending
mergeragreement;GAAPmeasuresaffectedinthisreleaseincludeconsolidatedpretaxincomeandEPS.
Amortizationexpenseforidentifiableintangiblesofapproximately$41million,or$0.17perdilutedcommonshare;GAAPmeasures
affectedinthisreleaseincludeconsolidatedpretax,EPS,andsegmentpretaxresults(foreachsegmentsamountofsuch
amortization).
Operatinglossesof$237millionpretax,or$1.08perdilutedcommonshare,forthecompanysIndividualCommercialbusiness
giventhecompanysplannedexitonJanuary1,2018,aspreviouslydisclosed.GAAPmeasuresaffectedinthisreleaseinclude
consolidatedpretaxincome,EPS,consolidatedrevenues,consolidatedbenefitratioandconsolidatedoperatingcostratio.
(e) FY17AdjustedEPSprojectionsexcludethefollowing:
Netgainfromtheterminationofthemergeragreementofapproximately$947millionpretax,or$4.36perdilutedcommonshare;
includesthenetbreakupfeeandtransactioncostsnetofthetaxbenefitassociatedwithcertainexpenseswhichwerepreviously
nondeductible.
Amortizationexpenseforidentifiableintangiblesofapproximately$71millionpretax,or$0.31perdilutedcommonshare.
20
Theoneyearbeneficialeffectofalowereffectivetaxrateofapproximately$2.15perdilutedcommonshareinlightofpricingand
benefitdesignassumptionsassociatedwiththe2017temporarysuspensionofthenondeductiblehealthinsuranceindustryfee;
excludesIndividualCommercialbusinessimpact.
Guarantyfundassessmentexpenseofapproximately$54millionpretax,or$0.24perdilutedcommonshare,tosupportthe
policyholderobligationsofPennTreaty(anunaffiliatedlongtermcareinsurancecompany).
Operatingresultsofapproximately$85millionpretax,or$0.37perdilutedcommonshare,forthecompanysIndividual
CommercialbusinessgiventhecompanysplannedexitonJanuary1,2018,aspreviouslydisclosed.
(f) FY16AdjustedEPS(recast)excludethefollowing:
Transactionandintegrationcostsof$104millionpretax,or$0.64perdilutedcommonshare,associatedwiththethenpending
mergeragreement.
Amortizationexpenseforidentifiableintangiblesofapproximately$77millionpretax,or$0.32perdilutedcommonshare.
Pretaxexpensesof$505million,or$2.11perdilutedcommonshare,ofreservestrengtheningrelatedtothecompanysnon
strategicclosedblockoflongtermcareinsurancebusiness.Seerelatedfootnote(g).
Operatinglossesof$869millionpretax,or$3.78perdilutedcommonshare,forthecompanysIndividualCommercialbusiness
giventhecompanysplannedexitonJanuary1,2018,aspreviouslydisclosed.Includesthewriteoffofreceivablesassociatedwith
theriskcorridorpremiumstabilizationprogram.Seerelatedfootnote(h).
(g) Asnotedabove,inadditiontopreviouslydisclosedadjustments,EPSforFY16includedastrengtheningofreservesforthecompanys
nonstrategicclosedblockoflongtermcarebusiness.InconnectionwithitsacquisitionofKMGAmericain2007,thecompanyacquired
anonstrategicclosedblockoflongtermcareinsurancepolicies.Thesepoliciesweresoldbetween1995and2005,ofwhich
approximately30,800remainedinforceasofDecember31,2016.Duringthefourthquarterof2016,thecompanyrecordedareserve
strengtheningforthisclosedblockofpoliciesasitdeterminedthepresentvalueoffuturepremiums,togetherwithitsexistingreserves
werenotadequatetoprovideforfuturepolicybenefits.Thisadjustmentprimarilywasdrivenbyemergingexperienceindicatinglonger
claimsduration,aprolongedlowerinterestrateenvironmentandanincreaseinpolicyholderlifeexpectancies.
(h) OnNovember10,2016,theU.S.CourtofFederalClaimsruledinfavorofthegovernmentinoneofaseriesofcasesfiledbyinsurers
againsttheDepartmentofHealthandHumanServices(HHS)tocollectriskcorridorpayments,rejectingalloftheinsurersstatutory,
contractandConstitutionalclaimsforpayment.Priortothisdecision,thecompanyhadmaintainedthereceivableinpreviousperiodsin
relianceupontheinterpretationpreviouslypromulgatedbyHHSthattheriskcorridorreceivableswereobligationsoftheU.S.
government.Giventhiscourtdecision,however,thecompanysconclusionwithrespecttotheultimatecollectabilityofthereceivable
shifted,andaccountingrulesrequiredthatthereceivablebewrittenoff.LandofLincolnMutualHealthInsuranceCompanyv.United
States;UnitedStatesCourtofFederalClaimsNo.16744C.
(i) Generally,whenthefirstdayofamonthfallsonaweekendorholiday,withtheexceptionofJanuary1(NewYearsDay),thecompany
receivesitsmonthlyMedicarepremiumpaymentfromCMSonthelastbusinessdayofthepreviousmonth.OnaGAAPbasis,thiscan
resultincertainquarterlycashflowsfromoperationsincludingmoreorlessthanthreemonthlypayments.Consequently,whenthis
occurs,thecompanyreportsAdjustedcashflowsfromoperationstoreflectthreepaymentsineachquartertomatchtherelated
expenses.
(j) Thecompanyprovidesafullrangeofinsuredspecialtyproductsincludingdental,vision,othersupplementalhealth,financialprotection,
andvoluntaryinsurancebenefitsmarketedtoindividualsandgroups.Membersincludedintheseproductsmaynotbeuniquetoeach
productsincemembershavetheabilitytoenrollinmultipleproducts.Othersupplementalbenefitsincludelife,disability,andfixed
benefitproductsincludingcancerandcriticalillnesspolicies.
CautionaryStatement
ThisnewsreleaseincludesforwardlookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995.Whenusedin
investorpresentations,pressreleases,SecuritiesandExchangeCommission(SEC)filings,andinoralstatementsmadebyorwiththeapprovalof
oneofHumanasexecutiveofficers,thewordsorphraseslikeexpects,believes,anticipates,intends,likelywillresult,estimates,
projectsorvariationsofsuchwordsandsimilarexpressionsareintendedtoidentifysuchforwardlookingstatements.
Theseforwardlookingstatementsarenotguaranteesoffutureperformanceandaresubjecttorisks,uncertainties,and
assumptions,including,amongotherthings,informationsetforthintheRiskFactorssectionofthecompanysSECfilings,a
summaryofwhichincludesbutisnotlimitedtothefollowing:
IfHumanadoesnotdesignandpriceitsproductsproperlyandcompetitively,ifthepremiumsHumanareceivesareinsufficienttocover
thecostofhealthcareservicesdeliveredtoitsmembers,ifthecompanyisunabletoimplementclinicalinitiativestoprovideabetter
healthcareexperienceforitsmembers,lowercostsandappropriatelydocumenttheriskprofileofitsmembers,orifitsestimatesof
benefitsexpenseareinadequate,Humanasprofitabilitycouldbemateriallyadverselyaffected.Humanaestimatesthecostsofitsbenefit
21
expensepayments,anddesignsandpricesitsproductsaccordingly,usingactuarialmethodsandassumptionsbasedupon,amongother
relevantfactors,claimpaymentpatterns,medicalcostinflation,andhistoricaldevelopmentssuchasclaiminventorylevelsandclaim
receiptpatterns.Thecompanycontinuallyreviewsestimatesoffuturepaymentsrelatingtobenefitexpensesforservicesincurredinthe
currentandpriorperiodsandmakesnecessaryadjustmentstoitsreserves,includingpremiumdeficiencyreserves,whereappropriate.
Theseestimates,however,involveextensivejudgment,andhaveconsiderableinherentvariabilitybecausetheyareextremelysensitive
tochangesinclaimpaymentpatternsandmedicalcosttrends,soanyreservesthecompanymayestablish,includingpremiumdeficiency
reserves,maybeinsufficient.
IfHumanafailstoeffectivelyimplementitsoperationalandstrategicinitiatives,particularlyitsMedicareinitiatives,statebasedcontract
strategy,anditsparticipationinthenewhealthinsuranceexchanges,thecompanysbusinessmaybemateriallyadverselyaffected,
whichisofparticularimportancegiventheconcentrationofthecompanysrevenuesintheseproducts.Inaddition,therecanbeno
assurancesthatthecompanywillbesuccessfulinmaintainingorimprovingitsStarratingsinfutureyears.
IfHumanafailstoproperlymaintaintheintegrityofitsdata,tostrategicallyimplementnewinformationsystems,toprotectHumanas
proprietaryrightstoitssystems,ortodefendagainstcybersecurityattacks,thecompanysbusinessmaybemateriallyadversely
affected.
Humanaisinvolvedinvariouslegalactions,ordisputesthatcouldleadtolegalactions(suchas,amongotherthings,providercontract
disputesrelatingtorateadjustmentsresultingfromtheBalancedBudgetandEmergencyDeficitControlActof1985,asamended,
commonlyreferredtoassequestration;otherprovidercontractdisputes;andquitamlitigationbroughtbyindividualsonbehalfofthe
government)andgovernmentalandinternalinvestigations,anyofwhich,ifresolvedunfavorablytothecompany,couldresultin
substantialmonetarydamagesorchangesinitsbusinesspractices.Increasedlitigationandnegativepublicitycouldalsoincreasethe
companyscostofdoingbusiness.
Asagovernmentcontractor,Humanaisexposedtorisksthatmaymateriallyadverselyaffectitsbusinessoritswillingnessorabilityto
participateingovernmenthealthcareprogramsincluding,amongotherthings,lossofmaterialgovernmentcontracts,governmental
auditsandinvestigations,potentialinadequacyofgovernmentdeterminedpaymentrates,potentialrestrictionsonprofitability,including
bycomparisonofprofitabilityofthecompanysMedicareAdvantagebusinesstononMedicareAdvantagebusiness,orotherchangesin
thegovernmentalprogramsinwhichHumanaparticipates.
TheHealthcareReformLaw,includingThePatientProtectionandAffordableCareActandTheHealthcareandEducationReconciliation
Actof2010,couldhaveamaterialadverseeffectonHumanasresultsofoperations,includingrestrictingrevenue,enrollmentand
premiumgrowthincertainproductsandmarketsegments,restrictingthecompanysabilitytoexpandintonewmarkets,increasingthe
companysmedicalandoperatingcostsby,amongotherthings,requiringaminimumbenefitratiooninsuredproducts,loweringthe
companysMedicarepaymentratesandincreasingthecompanysexpensesassociatedwithanondeductiblehealthinsuranceindustry
feeandotherassessments;thecompanysfinancialposition,includingthecompanysabilitytomaintainthevalueofitsgoodwill;andthe
companyscashflows.Additionally,potentiallegislativechanges,includingactivitiestorepealorreplace,inwholeorinpart,theHealth
CareReformLaw,createsuncertaintyforHumanasbusiness,andwhen,orinwhatform,suchlegislativechangesmayoccurcannotbe
predictedwithcertainty.
Humanascontinuedparticipationinthefederalandstatehealthinsuranceexchanges,whichentailuncertaintiesassociatedwithmix,
volumeofbusinessandtheoperationofpremiumstabilizationprogramsthataresubjecttofederaladministrativeaction,could
adverselyaffectthecompanysresultsofoperations,financialpositionandcashflows.
Humanasbusinessactivitiesaresubjecttosubstantialgovernmentregulation.Newlawsorregulations,orchangesinexistinglawsor
regulationsortheirmannerofapplicationcouldincreasethecompanyscostofdoingbusinessandmayadverselyaffectthecompanys
business,profitabilityandcashflows.
IfHumanafailstodevelopandmaintainsatisfactoryrelationshipswiththeprovidersofcaretoitsmembers,thecompanysbusinessmay
beadverselyaffected.
Humanaspharmacybusinessishighlycompetitiveandsubjectsittoregulationsinadditiontothosethecompanyfaceswithitscore
healthbenefitsbusinesses.
ChangesintheprescriptiondrugindustrypricingbenchmarksmayadverselyaffectHumanasfinancialperformance.
IfHumanadoesnotcontinuetoearnandretainpurchasediscountsandvolumerebatesfrompharmaceuticalmanufacturersatcurrent
levels,Humanasgrossmarginsmaydecline.
Humanasabilitytoobtainfundsfromcertainofitslicensedsubsidiariesisrestrictedbystateinsuranceregulations.
DowngradesinHumanasdebtratings,shouldtheyoccur,mayadverselyaffectitsbusiness,resultsofoperations,andfinancialcondition.
Thesecuritiesandcreditmarketsmayexperiencevolatilityanddisruption,whichmayadverselyaffectHumanasbusiness.
Inmakingforwardlookingstatements,Humanaisnotundertakingtoaddressorupdatetheminfuturefilingsorcommunicationsregardingits
businessorresults.Inlightoftheserisks,uncertainties,andassumptions,theforwardlookingeventsdiscussedhereinmayormaynotoccur.There
alsomaybeotherrisksthatthecompanyisunabletopredictatthistime.Anyoftheserisksanduncertaintiesmaycauseactualresultstodiffer
materiallyfromtheresultsdiscussedintheforwardlookingstatements.
22
HumanaadvisesinvestorstoreadthefollowingdocumentsasfiledbythecompanywiththeSECforfurtherdiscussionbothoftherisksitfacesand
itshistoricalperformance:
Form10KfortheyearendedDecember31,2016;
Form10QforthequarterendedMarch31,2017;and
Form8Ksfiledduring2017.
AboutHumana
HumanaInc.iscommittedtohelpingourmillionsofmedicalandspecialtymembersachievetheirbesthealth.Our
successfulhistoryincaredeliveryandhealthplanadministrationishelpinguscreateanewkindofintegratedcarewith
thepowertoimprovehealthandwellbeingandlowercosts.Oureffortsareleadingtoabetterqualityoflifeforpeople
withMedicare,families,individuals,militaryservicepersonnel,andcommunitiesatlarge.
Toaccomplishthat,wesupportphysiciansandotherhealthcareprofessionalsastheyworktodelivertherightcarein
therightplacefortheirpatients,ourmembers.Ourrangeofclinicalcapabilities,resourcesandtoolssuchasinhome
care,behavioralhealth,pharmacyservices,dataanalyticsandwellnesssolutionscombinetoproduceasimplified
experiencethatmakeshealthcareeasiertonavigateandmoreeffective.
MoreinformationregardingHumanaisavailabletoinvestorsviatheInvestorRelationspageofthecompanyswebsite
athumana.com,includingcopiesof:
Annualreportstostockholders;
SecuritiesandExchangeCommissionfilings;
Mostrecentinvestorconferencepresentations;
Quarterlyearningsnewsreleasesandconferencecalls;
Calendarofevents;and
CorporateGovernanceinformation.
23
HumanaInc.RollforwardofInitial2017GuidancetoCurrent2017
Guidance GenerallyAccepted
Dilutedearningspercommonshare(EPS) AccountingPrinciples Adjustmentsto
(GAAP)EPS GAAP AdjustedEPS
GuidanceissuedonFebruary14,2017 $16.65to$16.85 (~5.85) $10.80to$11.00
Changesinprojectedoperatingperformance:
Retailsegment,largelyattributabletoPriorPeriodDevelopmentinthe
IndividualMedicareAdvantagebusiness $0.20 $0.20
Other ($0.04) $0.04
GuidancerevisedApril24,2017 Atleast$16.91 (~5.81) Atleast$11.10
Changesinprojectedoperatingperformance:
Retailsegment,largelyattributabletotheIndividualMedicare
Advantagebusiness $1.16 $1.16
Group&Specialtysegment $0.09 $0.09
HealthcareServicessegment ($0.60) ($0.60)
IndividualCommercialsegment $0.52 ($0.52)
Other ($0.25) ($0.25)
GuidanceasofAugust2,2017 Approximately$17.83 (~6.33) Approximately$11.50
24
Inaccordance HumanaInc. Comments
withGAAP FullYear2017Projections
unless AsofAugust2,2017
otherwise
noted
Dilutedearnings GAAP ~$17.83 Seefootnote(e)fordetailofnonGAAP
Adjustments ($6.33) adjustments
percommon
share(EPS) NonGAAP ~$11.50
Consolidatedrevenuesinclude~$950
millioninrevenuesassociatedwiththe
IndividualCommercialbusiness(ACA
compliantandnonACAcompliant
combined)
HealthcareServicessegmentrevenues
includetheimpactofthecontinued
optimizationofthecompanysHumana
AtHomebusiness,whichisproceeding
slightlyaheadofpreviousexpectations.
Additionally,thecompanyis
experiencinglowerthanpreviously
expectedpharmacyvolumes.
Benefitratios Ratiocalculation:benefitsexpenseas
Retailsegment 85.25%to85.75% apercentofpremiumrevenues
Nomaterialimpactanticipatedfrom
GroupandSpecialtysegment 79.75%to80.25%
nonGAAPadjustments
25
Inaccordance HumanaInc. Comments
withGAAP FullYear2017Projections
unless AsofAugust2,2017
otherwise
noted
Pretaxresults Nomaterialimpactanticipatedfrom
Retailsegment $2.05billionto$2.15billion nonGAAPadjustmentsonsegment
levelresultsfortheRetail,Groupand
Specialty,orHealthcareServices
GroupandSpecialtysegment $320millionto$340million segments
ThecompanyexpectsIndividual
HealthcareServicessegment $925millionto$975million Commercialsegmentpretaxearnings
of~$85million
Effectivetax GAAP 36%to37% Seefootnote(e)fordetailofnonGAAP
Adjustments ~11.0% adjustments
rate
NonGAAP 47%to48%
26
Humana Inc.
Statistical Schedules
And
Supplementary Information
2Q17 Earnings Release
S-1
Humana Inc.
Statistical Schedules and Supplementary Information
2Q17 Earnings Release
Contents
Consolidated Financial Statements
1. Consolidated Statements of Income (S-3 - S-4)
2. Consolidated Balance Sheets (S-5)
3. Consolidated Statements of Cash Flows (S-6 - S-7)
Operating Results Detail
4. Consolidating Statements of Income - Quarter (S-8 - S-9)
5. Consolidating Statements of Income - YTD (S-10 - S-11)
6. Ending Membership Detail (S-12)
7. Premiums and Services Revenue Detail (S-13 - S-14)
8. Healthcare Services Segment Metrics (S-15 - S-17)
Balance Sheet Detail
9. Benefits Payable Detail and Statistics (S-18 - S-19)
Footnotes (S-20)
S-2
Humana Inc.
Consolidated Statements of Income
Dollars in millions, except per common share results
Shares used in computing basic earnings per common share (000's) 144,600 149,386
Shares used in computing diluted earnings per common share (000's) 145,634 150,806
S-3
Humana Inc.
Consolidated Statements of Income
Dollars in millions, except per common share results
Shares used in computing basic earnings per common share (000's) 146,212 149,273
Shares used in computing diluted earnings per common share (000's) 147,253 150,851
S-4
Humana Inc.
Consolidated Balance Sheets
Dollars in millions, except share amounts
June 30, December 31, YTD Change
2017 2016 Dollar Percent
Assets
Current assets:
Cash and cash equivalents $ 8,139 $ 3,877
Investment securities 8,115 7,595
Receivables, net 2,430 1,280
Other current assets 3,884 3,438
Total current assets 22,568 16,190 $ 6,378 39.4%
Return on Invested Capital (ROIC) based on Net Operating Profit 12.6% 5.0%
After Tax (NOPAT) - trailing 12 months
S-5
Humana Inc.
Consolidated Statements of Cash Flows
Dollars in millions
Three Months Ended June 30,
Dollar Percentage
2017 2016 Change Change
Cash flow s from operating activities
Net income $ 650 $ 311
Adjustments to reconcile net income to net cash used in
operating activities:
Depreciation 101 96
Other intangible amortization 18 20
Net realized capital gains (2) (19)
Stock-based compensation 57 25
Benefit from deferred income taxes (27) (39)
Changes in operating assets and liabilities, net of
effect of businesses acquired and dispositions:
Receivables (592) (816)
Other assets (130) 7
Benefits payable 77 144
Other liabilities (225) (12)
Unearned revenues (64) (49)
Other, net 31 36
Net cash used in operating activities (106) (296) $190 64.2%
S-6
Humana Inc.
Consolidated Statements of Cash Flows
Dollars in millions
Six Months Ended June 30,
Dollar Percentage
2017 2016 Change Change
Cash flow s from operating activities
Net income $ 1,765 $ 565
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation 201 190
Other intangible amortization 36 41
Net realized capital gains (28) (39)
Stock-based compensation 83 48
Provision (benefit) for deferred income taxes 2 (24)
Changes in operating assets and liabilities, net of
effect of businesses acquired and dispositions:
Receivables (1,150) (1,392)
Other assets (545) (678)
Benefits payable 275 282
Other liabilities 317 1,198
Unearned revenues 3,076 (53)
Other, net 67 68
Net cash provided by operating activities 4,099 206 $3,893 1889.8%
S-7
Humana Inc.
Consolidating Statements of Income - 2Q17
In millions
Intersegment revenues
Services - 5 4,309 - - (4,314) -
Products - - 1,582 - - (1,582) -
Total intersegment revenues - 5 5,891 - - (5,896) -
Investment income 24 7 8 1 21 40 101
Total revenues 11,299 1,828 5,982 248 33 (5,856) 13,534
Operating expenses:
Benefits 9,672 1,312 - 86 32 (213) 10,889
Operating costs 963 394 5,677 40 2 (5,623) 1,453
Depreciation and amortization 57 21 35 4 - (25) 92
Total operating expenses 10,692 1,727 5,712 130 34 (5,861) 12,434
Income (loss) from operations 607 101 270 118 (1) 5 1,100
Interest expense - - - - - 58 58
Income (loss) before income taxes $ 607 $ 101 $ 270 $ 118 $ (1) $ (53) $ 1,042
S-8
Humana Inc.
Consolidating Statements of Income - 2Q16 (Recast) (C )
In millions
Intersegment revenues
Services - 6 4,767 - - (4,773) -
Products - - 1,433 - - (1,433) -
Total intersegment revenues - 6 6,200 - - (6,206) -
Investment income 22 6 7 1 16 43 95
Total revenues 10,958 1,871 6,288 1,025 28 (6,163) 14,007
Operating expenses:
Benefits 9,327 1,302 - 1,089 31 (240) 11,509
Operating costs 1,069 423 5,974 152 4 (5,923) 1,699
Merger termination fee and related costs, net - - - - - 27 27
Depreciation and amortization 48 22 35 9 - (25) 89
Total operating expenses 10,444 1,747 6,009 1,250 35 (6,161) 13,324
Income (loss) from operations 514 124 279 (225) (7) (2) 683
Interest expense - - - - - 47 47
Income (loss) before income taxes $ 514 $ 124 $ 279 $ (225) $ (7) $ (49) $ 636
Intersegment revenues
Services - 10 8,619 - - (8,629) -
Products - - 3,134 - - (3,134) -
Total intersegment revenues - 10 11,753 - - (11,763) -
Investment income 49 18 16 2 42 85 212
Total revenues 22,732 3,705 11,940 532 65 (11,678) 27,296
Operating expenses:
Benefits 19,723 2,598 - 242 61 (409) 22,215
Operating costs 1,917 793 11,357 102 6 (11,169) 3,006
Merger termination fee and related costs, net - - - - - (947) (947)
Depreciation and amortization 115 42 69 7 - (49) 184
Total operating expenses 21,755 3,433 11,426 351 67 (12,574) 24,458
Income (loss) from operations 977 272 514 181 (2) 896 2,838
Interest expense - - - - - 107 107
Income (loss) before income taxes $ 977 $ 272 $ 514 $ 181 $ (2) $ 789 $ 2,731
Intersegment revenues
Services - 12 9,551 - - (9,563) -
Products - - 2,793 - - (2,793) -
Total intersegment revenues - 12 12,344 - - (12,356) -
Investment income 46 12 14 3 31 89 195
Total revenues 21,860 3,720 12,518 1,920 56 (12,267) 27,807
Operating expenses:
Benefits 18,960 2,524 - 1,818 56 (452) 22,906
Operating costs 2,151 857 11,916 321 8 (11,820) 3,433
Merger termination fee and related costs, net - - - - - 61 61
Depreciation and amortization 94 43 71 18 - (49) 177
Total operating expenses 21,205 3,424 11,987 2,157 64 (12,260) 26,577
Income (loss) from operations 655 296 531 (237) (8) (7) 1,230
Interest expense - - - - - 94 94
Income (loss) before income taxes $ 655 $ 296 $ 531 $ (237) $ (8) $ (101) $ 1,136
Individual com m ercial 181.1 187.9 792.0 (610.9) -77.1% 654.8 (473.7) -72.3%
Other Businesses
Long-term care 30.3 30.4 31.4 (1.1) -3.5% 30.8 (0.5) -1.6%
Total Other Businesses 30.3 30.4 31.4 (1.1) -3.5% 30.8 (0.5) -1.6%
Total Medical Mem bership 13,971.8 13,963.1 14,245.1 (273.3) -1.9% 14,230.2 (258.4) -1.8%
Dental - fully-insured 2,963.2 2,960.0 2,969.6 (6.4) -0.2% 2,952.4 10.8 0.4%
Dental - ASO 681.6 683.4 702.4 (20.8) -3.0% 702.0 (20.4) -2.9%
Vision 2,133.4 2,131.5 2,134.2 (0.8) 0.0% 2,136.0 (2.6) -0.1%
Other supplemental benef its (E) 1,139.6 1,143.9 1,196.1 (56.5) -4.7% 1,170.8 (31.2) -2.7%
Total Specialty Mem bership 6,917.8 6,918.8 7,002.3 (84.5) -1.2% 6,961.2 (43.4) -0.6%
S-12
Humana Inc.
Premiums and Services Revenue Detail
Dollars in millions, except per member per month
Healthcare Services
Pharmacy solutions 5,214 5,442 (228) -4.2%
Provider services 414 446 (32) -7.2%
Clinical programs 346 393 (47) -12.0%
Total Healthcare Services 5,974 6,281 (307) -4.9%
S-13
Humana Inc.
Premiums and Services Revenue Detail
Dollars in millions, except per member per month
Healthcare Services
Pharmacy solutions 10,373 10,856 (483) -4.4%
Provider services 852 884 (32) -3.6%
Clinical programs 699 764 (65) -8.5%
Total Healthcare Services 11,924 12,504 (580) -4.6%
S-14
Humana Inc.
Healthcare Services Segment Metrics
S-15
Humana Inc.
Healthcare Services Segment Metrics (Continued)
Script volume in thousands
Pharmacy:
Generic Dispense Rate
Retail 91.4% 90.6% 0.8% 91.4% 0.0%
Group and Specialty 86.4% 84.7% 1.7% 86.4% 0.0%
Individual Commercial 89.7% 88.8% 0.9% 90.4% -0.7%
Mail-Order Penetration
Retail 29.1% 28.7% 0.4% 29.2% -0.1%
Group and Specialty 7.3% 7.8% -0.5% 7.2% 0.1%
Individual Commercial 4.3% 3.9% 0.4% 4.1% 0.2%
Percentage Percentage
Difference Change Difference Change
Script volum e (L) 107,900 105,000 2,900 2.8% 107,000 900 0.8%
S-16
Humana Inc.
Healthcare Services Segment Metrics (Continued)
Script volume in thousands
Pharmacy:
Generic Dispense Rate
Retail 91.4% 90.5% 0.9%
Group and Specialty 86.4% 84.6% 1.8%
Individual Commercial 90.0% 89.2% 0.8%
Mail-Order Penetration
Retail 29.1% 28.7% 0.4%
Group and Specialty 7.2% 7.8% -0.6%
Individual Commercial 4.2% 3.7% 0.5%
Percentage
Difference Change
S-17
Humana Inc.
Detail of Benefits Payable Balance and Year-to-Date Changes
Dollars in millions
S-18
Humana Inc.
Benefits Payable Statistics (Continued) (S)
S-19
HumanaInc.
FootnotestoStatisticalSchedulesandSupplementaryInformation
2Q17EarningsRelease
(A) TheMedicaidandothercategoryincludespremiumsassociatedwiththecompanysMedicaidandmilitaryservicesbusinessesaswellastheclosedblockoflongtermcareinsurancepolicies.
(B) TheASOandothercategoryisprimarilycomprisedofAdministrativeServicesOnly(ASO)feesandotherancillaryservicesfees,includingMilitaryservicesunlessseparatelydisclosed.
(C) OnJanuary1,2017,thecompanyrealignedcertainofitsbusinessesamongitsfinancialreportingsegmentstocorrespondwithinternalmanagementreportingchangesandrenameditsGroupsegmenttheGroup
andSpecialtysegment.ThecompanysreportablesegmentsareRetail,GroupandSpecialty,HealthcareServices,andIndividualCommercial.
(D) IncludesMedicaidTemporaryAssistanceforNeedyFamilies(TANF),dualeligibledemonstration,andLongTermSupportServices(LTSS)fromstatebasedcontracts.
(E) Othersupplementalbenefitsincludelife,disability,andfixedbenefitproductsincludingcancerandcriticalillnesspolicies.
(F) Incertaincircumstances,thecompanycontractswithproviderstoacceptfinancialriskforadefinedsetofMedicareAdvantagemembership.Intransferringthisrisk,thecompanyprepaystheseprovidersa
monthlyfixedfeepermembertocoordinatesubstantiallyallofthemedicalcarefortheirMedicareAdvantagemembersassignedorattributedtotheirproviderpanel,includingsomehealthbenefit
administrativefunctionsandclaimsprocessing.ForthesecapitatedSharedRiskarrangements,thecompanygenerallyagreestopaymentratesthattargetabenefitexpenseratio.Theresultisahighlevelof
engagementonthepartoftheprovider.
(G) APathtoRiskproviderisonewhohasahighlevelofengagementandparticipatesinoneofHumanaspayforperformanceprograms(ModelPracticeorMedicalHome)orhasariskcontractinplacewitha
trigger(futuredateormembershipthreshold)whichhasnotyetbeenmet.Inadditiontoearningincentives,theseprovidersmayalsohaveasharedsavingscomponentbywhichtheycanshareinachieved
surpluseswhentheactualcostofthemedicalservicesprovidedtopatientsassignedorattributedtotheirpanelislessthantheagreeduponmedicalexpensetarget.
(H) ThemajorityofmilitaryservicesrevenuesaregenerallynotcontractedonapermemberbasisunderthecurrentTRICARESouthRegioncontract.
(I) Computedbasedonaveragemembershipfortheperiod(i.e.,monthlyendingmembershipduringtheperioddividedbythenumberofmonthsintheperiod).
(J) IncludesMedicareAdvantage(includingSpecialNeedsPlans(SNP))anddualeligibledemonstrationprogrammembersenrolledinoneofHumanaschroniccareprograms.Thesemembersmaybeenrolledin
HumanaAtHomeChronicCareProgram(HCCP),HumanaAtHomeStayHealthy,HumanaAtHomeRemoteMonitoring,oranAdvanceIllnessSupportprogram.Membersincludedintheseprogramsmaynotbe
uniquetoeachprogramsincemembershavetheabilitytoenrollinmultipleprograms.
(K) ReflectsdischargesenrolledinHumanas30daycaremanagementservices,whichsupportsmembersaftertheyaredischargedhomefromahospitalorotherfacility.Theprogramisaimedatindividualsathigh
riskforrehospitalization.Caremanagersvisitandcallmembersathometoensuretheyhaveandunderstandcorrectprescriptions,theirdoctorsareinformedaboutmemberschangedstatus,andthatmembers
areeitherselfmanagingadequatelyorarereferredtoappropriateongoingservices.
(L) Scriptvolumeispresentedonanadjusted30dayequivalentbasis.
(M) IBNRrepresentsanestimateofbenefitsexpensepayableforclaimsincurredbutnotreported(IBNR)atthebalancesheetdate.ThelevelofIBNRisprimarilyimpactedbymembershiplevels,medicalclaimtrends
andthereceiptcycletime,whichrepresentsthelengthoftimebetweenwhenaclaimisinitiallyincurredandwhentheclaimformisreceived(i.e.ashortertimespanresultsinalowerIBNR).IBNRincludes
unprocessedclaimsinventories.
(N) Reportedclaimsinprocessrepresentstheestimatedvaluationofprocessedclaimsthatareinthepostclaimadjudicationprocess,whichconsistsofadministrativefunctionssuchasauditandcheckbatchingand
handling,aswellasamountsowedtothecompanyspharmacybenefitadministrator,whichfluctuateduetobiweeklypaymentsandthemonthendcutoff.
(O) Otherbenefitspayableprimarilyincludeamountsowedtoprovidersundercapitatedandrisksharingarrangements.
(P) RepresentsreinsurancerecoverablesassociatedwiththecompanysstatebasedMedicaidcontractinKentucky.
(Q) Amountsincurredrelatedtoprioryearsvaryfrompreviouslyestimatedliabilitiesastheclaimsultimatelyaresettled.Negativeamountsreportedforincurredrelatedtoprioryearsresultfromclaimsbeing
ultimatelysettledforamountslessthanoriginallyestimated(favorabledevelopment).Therewerenochangesintheapproachusedtodeterminethecompany'sestimateofmedicalclaimreservesduringthe
quarter.
(R) Futurepolicybenefitexpensehasarelatedliabilityclassifiedasalongtermliabilityonthebalancesheet.Amountsreflectthereleaseofreservesforfuturepolicybenefitsasindividualmedicalmembers
transitionedtoplanscompliantwiththeAffordableCareAct.
(S) Acommonmetricformonitoringbenefitspayablelevelsrelativetobenefitsexpenseisdaysinclaimspayable(DCP).During1Q17,thecompanysimplifieditsmethodologyforcalculatingDCPinordertoenhance
transparencyforinvestors,nowcalculatingDCPusingthequarterlyreportedbenefitsexpenseandbenefitspayablebalancesaspresentedwithinthecompanysconsolidatedfinancialstatements,adjustingsolely
forfuturepolicybenefitsexpenseassociatedwithreservestrengtheningforthecompanysnonstrategicblockoflongtermcareinsurancebusiness.
(T) DCPfluctuatesduetoanumberoffactors,themoresignificantofwhicharedetailedinthisrollforward.GrowthincertainproductlinescanalsoimpactDCPforthequartersinceaprovisionforclaimswouldnot
havebeenrecordedformembersthathadnotyetenrolledearlierinthequarter,yetthosememberswouldhaveaprovisionandcorrespondingmedicalclaimsreserverecordeduponenrollmentlaterinthequarter.
(U) Provideraccrualsrepresentportionsofcapitationpaymentssetasidetopayfuturesettlementsforcapitatedproviders.Relatedsettlementsgenerallyhappenovera12monthperiod.
(V) RepresentspaidandincurredmedicalandspecialtyclaimsfornonpharmacyfullyinsuredproductsandexcludestheimpactoftheIndividualCommercialsegment.
(W) RepresentsIndividualCommercialpaidandincurredmedicalclaims(onexchange,offexchange,andlegacy),aswellastheimpactofanypremiumdeficiencyreservesrelatedtothisblockofbusiness.
(X) RepresentspharmacyclaimsexpenseincludingpaymentstothecompanyspharmacybenefitmanagerforprescriptiondrugsfilledonbehalfofHumanasmembers,aswellasgovernmentsubsidizedprogramsfrom
MedicarePartDsuchaslowincomecostandreinsurancesubsidies,aswellascoveragegapdiscountprograms.
(Y) Includesprocessedclaimsthatareinthepostclaimadjudicationprocess,whichconsistsofoperatingfunctionssuchasaudit,checkbatchingandcheckhandling.TheseclaimsareincludedinIBNRlags,buthavenot
yetbeenmailedorreleasedfromHumana.
(Z) IncludesnonlaggedreservessuchasASOstoploss,lifereserves,andaccidentaldeathanddismemberment/accidentandhealth.Alsoincludesanexplicitprovisionforuncertainty(alsocalledaprovisionforadverse
deviation)intendedtoensuretheunpaidclaimliabilitiesareadequateundermoderatelyadverseconditions.
S-20